HomeCompareASCLF vs FCPT

ASCLF vs FCPT: Dividend Comparison 2026

ASCLF yields 110.50% · FCPT yields 6.05%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ASCLF wins by $5.88M in total portfolio value
10 years
ASCLF
ASCLF
● Live price
110.50%
Share price
$1.81
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.93M
Annual income
$2,132,830.87
Full ASCLF calculator →
FCPT
FCPT
● Live price
6.05%
Share price
$23.65
Annual div
$1.43
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.1K
Annual income
$5,775.28
Full FCPT calculator →

Portfolio growth — ASCLF vs FCPT

📍 ASCLF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodASCLFFCPT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ASCLF + FCPT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ASCLF pays
FCPT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ASCLF
Annual income on $10K today (after 15% tax)
$9,392.27/yr
After 10yr DRIP, annual income (after tax)
$1,812,906.24/yr
FCPT
Annual income on $10K today (after 15% tax)
$514.49/yr
After 10yr DRIP, annual income (after tax)
$4,908.99/yr
At 15% tax rate, ASCLF beats the other by $1,807,997.25/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ASCLF + FCPT for your $10,000?

ASCLF: 50%FCPT: 50%
100% FCPT50/50100% ASCLF
Portfolio after 10yr
$2.99M
Annual income
$1,069,303.08/yr
Blended yield
35.77%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on FCPT right now

ASCLF
No analyst data
Altman Z
61.0
Piotroski
1/9
FCPT
Analyst Ratings
5
Buy
10
Hold
Consensus: Hold
Price Target
$27.00
+14.2% upside vs current
Range: $25.00 — $29.00
Altman Z
1.4
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ASCLF buys
0
FCPT buys
0
No recent congressional trades found for ASCLF or FCPT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricASCLFFCPT
Forward yield110.50%6.05%
Annual dividend / share$2.00$1.43
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$5.93M$49.1K
Annual income after 10y$2,132,830.87$5,775.28
Total dividends collected$5.35M$24.1K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: ASCLF vs FCPT ($10,000, DRIP)

YearASCLF PortfolioASCLF Income/yrFCPT PortfolioFCPT Income/yrGap
1← crossover$21,750$11,049.72$11,401$700.92+$10.3KASCLF
2$45,733$22,460.60$13,064$864.84+$32.7KASCLF
3$93,072$44,137.91$15,051$1,072.48+$78.0KASCLF
4$183,537$83,949.70$17,442$1,337.22+$166.1KASCLF
5$351,102$154,717.47$20,340$1,677.08+$330.8KASCLF
6$652,287$276,608.54$23,880$2,116.57+$628.4KASCLF
7$1,178,220$480,272.57$28,241$2,689.36+$1.15MASCLF
8$2,071,454$810,758.34$33,660$3,442.07+$2.04MASCLF
9$3,548,616$1,332,160.25$40,456$4,439.95+$3.51MASCLF
10$5,929,850$2,132,830.87$49,063$5,775.28+$5.88MASCLF

ASCLF vs FCPT: Complete Analysis 2026

ASCLFStock

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. The company offers Ritonavir oral tablet, a pharmacokinetic booster of various oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid; ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating chronic hepatitis B (CHB) and human immunodeficiency virus functional cure; ASC42 for chronic hepatitis B functional cure; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC, ASC44F FDC, and ASC45F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma, drug resistant breast cancer, and KRAS mutant non-small cell lung cancer; ASC61 and ASC63 for advanced solid tumors; ASC60 to treat solid tumors; and ASC40 for the treatment of acne, Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People's Republic of China.

Full ASCLF Calculator →

FCPTREIT

FCPT, headquartered in Mill Valley, CA, is a real estate investment trust primarily engaged in the acquisition and leasing of restaurant properties. The Company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries.

Full FCPT Calculator →
📬

Get this ASCLF vs FCPT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ASCLF vs SCHDASCLF vs JEPIASCLF vs OASCLF vs KOASCLF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.